TSVT Company Profile and Key Details
NASDAQ : TSVT
2seventy bio
$5.00
00
At Close 4:00 PMNot Actively Trading
67.75
BESG ScoreESG Rating
Price Chart
Stock Price Today
2seventy bio, Inc. (TSVT) stock remained unchanged at $5.00 a share on NASDAQ. The stock opened at $5.00, fluctuating between $5.00 to $5.00 during the session.
Stock Snapshot
5
Prev. Close
266.14M
Market Cap
5
Day Low
-62.5
P/E Ratio
-0.08
EPS (TTM)
-3.52
Cash Flow per Share
5
Open
53.23M
Number of Shares
5
Day High
80.22%
Free Float in %
4.97
Book Value
1.16M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 22, 2025 | 5.00 | 5.00 | 5.00 | 5.00 | 0 |
| May 21, 2025 | 5.00 | 5.00 | 5.00 | 5.00 | 0 |
| May 12, 2025 | 5.00 | 5.01 | 4.99 | 5.00 | 1.16M |
| May 09, 2025 | 4.99 | 5.00 | 4.99 | 4.99 | 347.57K |
| May 08, 2025 | 5.00 | 5.00 | 4.99 | 5.00 | 337.41K |
| May 07, 2025 | 4.99 | 5.00 | 4.99 | 5.00 | 251.77K |
| May 06, 2025 | 5.00 | 5.01 | 4.99 | 4.99 | 1.14M |
| May 05, 2025 | 5.00 | 5.01 | 4.99 | 5.00 | 1.4M |
| May 02, 2025 | 4.99 | 5.00 | 4.98 | 5.00 | 1.2M |
| May 01, 2025 | 4.98 | 5.00 | 4.98 | 4.98 | 829.9K |
| Apr 30, 2025 | 4.98 | 5.00 | 4.98 | 4.99 | 1.2M |
| Apr 29, 2025 | 4.98 | 4.99 | 4.98 | 4.99 | 247.5K |
| Apr 28, 2025 | 4.98 | 4.99 | 4.98 | 4.99 | 287.06K |
| Apr 25, 2025 | 4.99 | 4.99 | 4.98 | 4.98 | 261.18K |
| Apr 24, 2025 | 4.98 | 4.99 | 4.98 | 4.99 | 541.53K |
| Apr 23, 2025 | 4.98 | 4.99 | 4.97 | 4.99 | 1.12M |
| Apr 22, 2025 | 4.98 | 4.99 | 4.98 | 4.99 | 516.86K |
| Apr 21, 2025 | 4.97 | 4.99 | 4.97 | 4.99 | 939.17K |
| Apr 17, 2025 | 4.97 | 4.99 | 4.97 | 4.98 | 443.67K |
| Apr 16, 2025 | 4.97 | 4.98 | 4.96 | 4.97 | 358.97K |
Contact Details
About Company
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
Company Information
| Employees | 65 |
| Beta | 1.05 |
| Sales or Revenue | $100.39M |
| 5Y Sales Change% | -0.131% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-4.64-0.50%
argenx SE$915.30REGN-13.35-1.97%
Regeneron Pharmaceuticals, Inc.$662.88MDGL20.04+3.67%
Madrigal Pharmaceuticals, Inc.$565.40UTHR-9.36-1.66%
United Therapeutics Corporation$554.34VRTX-23.82-4.56%
Vertex Pharmaceuticals Incorporated$498.43KRYS6.8+1.84%
Krystal Biotech, Inc.$375.40PRAX9.04+2.79%
Praxis Precision Medicines, Inc.$332.99KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY1.91+0.59%
Alnylam Pharmaceuticals, Inc.$323.50LGND-4.55-1.42%
Ligand Pharmaceuticals Incorporated$314.88Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 0.25%, SMA50 6.5%, SMA200 23.03%). The stock’s 14-day RSI is 72.25 (overbought), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -5.66% below its high and over 118.34% above its low.
Dividend & Fair Value
Dividend and splits history remains an important factor for investors monitoring long-term returns.
Earnings & Analyst Outlook
The latest quarter delivered EPS of $0.01. The next quarter is forecast at $nan. Next year's EPS is expected at $47.55. 2seventy bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2025, missed forecasts by -105.88%. The prior quarter beat by 34.78%. Over the last six quarters, Apple has recorded several small beats. These include 54.17% in May 01, 2024.
Shareholding & Insider Activity
2seventy bio, Inc. has 53.23 million shares outstanding. The public float is 41.98 million shares, elevated short interest at 7.51% of float. This equals 3.78 million shares. The short ratio is 3.25 days. Institutional investors hold 88.07% of the float. Insiders own 6.44%. Kynam Capital Management, LP holds 5.14 million shares, Casdin Capital, LLC has 2.00 million shares and Leschly Nick has 1.23 million shares.
Frequently Asked Questions
What is the current 2seventy bio, Inc. (TSVT) stock price?
2seventy bio, Inc. (NASDAQ: TSVT) stock price is $5.00 in the last trading session. During the trading session, TSVT stock reached the peak price of $5.00 while $5.00 was the lowest point it dropped to. The percentage change in TSVT stock occurred in the recent session was 0% while the dollar amount for the price change in TSVT stock was $0.00.
TSVT's industry and sector of operation?
The NASDAQ listed TSVT is part of Biotechnology industry that operates in the broader Healthcare sector. 2seventy bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of TSVT?
Ms. Nicola H. Heffron
Chief Operating Officer
Ms. Kathleen A. Wilkinson
Chief People Officer
Mr. Nick Leschly
Pres, Chief Executive Officer & Director
Dr. Philip D. Gregory D. Phil., DPHIL
Chief Scientific Officer
Ms. Teresa L. Jurgensen J.D.
Vice President, Gen. Counsel & Corporation Sec.
Dr. Steven Bernstein M.D.
Chief Medical Officer
Michael Certo
Vice President & Head of Genome Editing
Mr. William D. Baird III, M.B.A.
Chief Financial Officer
Ms. Susan Abu-Absi Ph.D.
Chief Technology & Manufacturing Officer
Mr. Kevin Chin M.D., M.S.
Head of Clinical Devel.
Mr. Steven Shamah Ph.D.
Head of Oncology Research
Dr. Melissa Price Ph.D.
Senior Vice President of Devel. Operations
Ms. Jenn Snyder
Senior Vice President of Corporation Affairs
Mr. William D. Baird III
Chief Financial Officer
Chief Operating Officer
Ms. Kathleen A. Wilkinson
Chief People Officer
Mr. Nick Leschly
Pres, Chief Executive Officer & Director
Dr. Philip D. Gregory D. Phil., DPHIL
Chief Scientific Officer
Ms. Teresa L. Jurgensen J.D.
Vice President, Gen. Counsel & Corporation Sec.
Dr. Steven Bernstein M.D.
Chief Medical Officer
Michael Certo
Vice President & Head of Genome Editing
Mr. William D. Baird III, M.B.A.
Chief Financial Officer
Ms. Susan Abu-Absi Ph.D.
Chief Technology & Manufacturing Officer
Mr. Kevin Chin M.D., M.S.
Head of Clinical Devel.
Mr. Steven Shamah Ph.D.
Head of Oncology Research
Dr. Melissa Price Ph.D.
Senior Vice President of Devel. Operations
Ms. Jenn Snyder
Senior Vice President of Corporation Affairs
Mr. William D. Baird III
Chief Financial Officer
How TSVT did perform over past 52-week?
TSVT's closing price is 118.34% higher than its 52-week low of $2.29 where as its distance from 52-week high of $5.30 is -5.66%.
How many employees does TSVT have?
Number of TSVT employees currently stands at 65.
Link for TSVT official website?
Official Website of TSVT is: https://www.2seventybio.com
How do I contact TSVT?
TSVT could be contacted at phone 339 499 9300 and can also be accessed through its website. TSVT operates from 60 Binney Street, Cambridge, MA 02142, United States.
How many shares of TSVT are traded daily?
TSVT stock volume for the day was 1.16M shares. The average number of TSVT shares traded daily for last 3 months was 1.46M.
What is the market cap of TSVT currently?
The market value of TSVT currently stands at $266.14M with its latest stock price at $5.00 and 53.23M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep